Anvisa approves the import of 2 million doses of Oxford vaccine | Wellness

On October 23, Anvisa had already authorized the importation of 6 million doses of CoronaVac, a vaccine against Covid-19 developed by the Chinese laboratory Sinovac and tested in Brazil in partnership with the Butantan Institute.

In the request made by Fiocruz, it is indicated that vaccines arrive in the country in January. Importation is considered exceptional because the immunizer has not yet been submitted for authorization for emergency use or health registration.

According to the agency, the approval was carried out on December 31, 2020, the same day that Fiocruz, responsible for producing the vaccine, presented the import order.

• OXFORD VACCINE: See Fiocruz production schedule

Also according to Anvisa, because it is the importation of vaccine that has not yet been approved in the country, the entry of the material into the country must follow certain conditions. The main, says the agency, that The imported vaccines remain in the specific custody of Fiocruz until Anvisa authorizes the use of the product in the country.

On Friday, Anvisa said it finished analyzing the documents already submitted by AstraZeneca on the vaccine. In practice, this means that the agency “is up to date” with what has been presented so far.

A study published and reviewed in the scientific journal “Lancet” says that the Oxford vaccine has an average effectiveness of 70% and is safe. The tests were carried out in several countries, including Brazil. As an advantage, the technology used by the immunizer is one of production, storage and distribution considered easier.

At the end of December, the United Kingdom and Argentina authorized the emergency use of the Oxford vaccine. Learn more about the Oxford vaccine below

• The vaccine was 90% effective when given in a half dose followed by a full dose at least a month apart, according to data from tests in the UK.
• When given in 2 full doses, the efficacy was 62%.
• The analysis that considered both types of dosage indicated an average effectiveness of 70.4%.
• To arrive at the results, the researchers analyzed data from 11,636 vaccinated people. Of these, 8,895 received the two full doses and 2,741 received half the dose followed by a full dose.
• Approximately 88% of the volunteers analyzed (10,218) were between 18 and 55 years old.
• No participant 56 years or older received half the dose followed by the full dose, which was more effective
• The efficacy of the vaccine has not been evaluated in participants older than 56 years, but will be determined in future analyzes.
• Researchers are investigating the potential of the vaccine to prevent asymptomatic cases of Covid-19.

See more news about Covid-19 vaccines in the VIDEOS below